BRCA2 and prostate carcinoma: Transient overexpression of BRCA2 in prostate cancer cells resulted per se’ in decreased cell proliferation, increased apoptosis and resistance to 6-TG, PTX or a combination of them (Figure 5D and Supplementary Figure S1).